The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
Open accessAbstract
Purpose: To detect immunoglobulins in aqueous humour of AMD patients after repeated administration of intravitreal aflibercept. Patients and methods: Twenty-one patients (age: 77.85 ± 9.21 years) previously treated with intravitreal aflibercept due to wet type age-related macular degeneration (AMD group) and 18 age-matched control subjects (age: 69.75 ± 12.67 years) were included in this study. Patients in the AMD group received a mean of 5 intravitreal injections (min: 1 max: 17) prior to the cataract surgery. Samples of aqueous humour (50 μl) were obtained by anterior chamber paracentesis as the first step of routine cataract surgery. The IgG content of the samples was analysed by an in-house developed ELISA system. Results: A significant increase in nonspecific IgG levels in the AMD group was detected compared to the control group (13.37 ± 6.65 vs. 9.44 ± 6.55 μg/ml; p = 0.03). In 11 patients, intraocular anti-aflibercept immunoglobulins could be detected (0.05 ± 0.01 μg/ml) which was significantly higher than the limit of detection for anti-aflibercept (0.04 μg/ml; p = 0.001). No correlation was found between the number of injections or the type of CNV and the aqueous level of anti-aflibercept (r = 0.02; p = 0.95). Conclusion: According to our results, penetration of non-specific systemic antibodies through the impaired blood-retinal barrier is higher in patients with neovascular AMD than in subjects with an intact structural barrier. Evaluation of neutralizing antibodies to anti-VEGF agents in the aqueous humour can lead us to understanding tachyphylaxis and changes in intraocular immune mechanisms due to AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The blood-ocular barrier restricts the passage of systemic antibodies into the intraocular space,26 although the functionality of this barrier can be compromised in certain disease states.27”
From Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes (2025) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“Approximately 30–50 million people are affected by AMD worldwide [3].”
BackgroundIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485 · cited 1×
“, Tarrytown, NY) is a recombinant fusion protein that binds to all VEGF-A, VEGF-B isoforms and growth factor [13, 14], and is the third approved anti-VEGF agent.”
BackgroundThe Five-year Incidence and Progression of Age-related Maculopathy
Klein, R., Klein, B. E. K., Jensen, S. C., & Meuer, S. M. (1997) · Ophthalmology · doi:10.1016/s0161-6420(97)30368-6 · Cited by 1,135
Visual Impairment and Falls in Older Adults: The Blue Mountains Eye Study
BOptom, R. Q. I., Cumming, R. G., Mitchell, P., & Attebo, K. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb01014.x · Cited by 734
Para-Inflammation in the Aging Retina
Xu, H., Chen, M., & Forrester, J. V. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.06.001 · Cited by 659 · cited 1×
“Dysregulated parainflammation in AMD weakens the blood retina barrier, resulting in the damage of retinal-immune privilege [39, 40].”
BackgroundHolz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Cortez, R., Hoyng, C. B., Hykin, P., Staurenghi, G., Heldner, S., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305327 · Cited by 615
Cunha-Vaz, J., Bernardes, R., & Lobo, C. (2011) · European Journal of Ophthalmology · doi:10.5301/ejo.2010.6049 · Cited by 539 · cited 1×
“The nonfenestrated capillaries of retinal vessels and the retinal pigment epithelium serve a membrane function with tight junctions [43].”
BackgroundIdentification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor.
Cousins, S. W., McCabe, M. M., Danielpour, D., & Streilein, J. W. (1991) · PubMed · Cited by 477
Grossniklaus, H. E., Ling, J. X., Wallace, T. M., Dithmar, S., Lawson, D., Cohen, C., Elner, V. M., Elner, S. G., & Sternberg, P. (2002) · PubMed · Cited by 434
Research works printed but not linked: 20
- Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains eye study. J Am Geriatr Soc. 1998;46(1):58–64. https://doi.org/10.1111/j.1532-5415.1998.tb01014.x. · DOI · Paper page
- West SK, Munoz B, Rubin GS, Schein OD, Bandeen-Roche K, Zeger S, et al. Function and visual impairment in a population-based study of older adults. The SEE project. Salisbury eye evaluation. Invest Ophthalmol Vis Sci. 1997;38(1):72–82.
- Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
- Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21–3. https://doi.org/10.1136/bjo.2011.203893. · DOI · Paper page
- Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
- Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
- Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
- Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31. https://doi.org/10.1056/NEJMoa054481. · DOI · Paper page
- Chen M, Xu H. Parainflammation, chronic inflammation, and age-related macular degeneration. J Leukoc Biol. 2015;98(5):713–25. https://doi.org/10.1189/jlb.3RI0615-239R. · DOI · Paper page
- Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol. 2011;21(Suppl 6):S3–9. https://doi.org/10.5301/EJO.2010.6049. · DOI · Paper page
- Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res. 1999;18(3):357–70. https://doi.org/10.1016/s1350-9462(98)00022-6. · DOI
- Streilein JW. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye (Lond). 1995;9(Pt 2):236–40. https://doi.org/10.1038/eye.1995.46. · DOI
- Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res. 1999;18(3):357–70. https://doi.org/10.1016/s1350-9462(98)00022-6. · DOI
- Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res. 1999;18(3):357–70. https://doi.org/10.1016/s1350-9462(98)00022-6. · DOI
- Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009;29(6):723–31. https://doi.org/10.1097/IAE.0b013e3181a2c1c3. · DOI · Paper page
- Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
- Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
- Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
- Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;2(10):1857–67. https://doi.org/10.2147/DDDT.S97653. · DOI · Paper page
- Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer DV. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther. 2015;22(2):116–26. https://doi.org/10.1038/gt.2014.115. · DOI · Paper page
Cited by
Durrani, A. F., Momenaei, B., Wakabayashi, T., Vemula, S., Pandit, S. A., Hsu, J., Ho, A. C., Spirn, M. J., Klufas, M. A., Garg, S. J., et al. (2024) · British Journal of Ophthalmology · doi:10.1136/bjo-2023-324394 · Cited by 23
Gene therapy for age-related macular degeneration: potential, feasibility, and pitfalls
Berkowitz, S. T., & Finn, A. P. (2024) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001043 · Cited by 9
Poulsen, K., Hanna, K., Nieves, J., Nguyen, N., Sharma, P., Grishanin, R., Corbau, R., & Kiss, S. (2025) · Molecular Therapy Methods & Clinical Development · doi:10.1016/j.omtm.2025.101430 · Cited by 8
Self-citationNagaoka, K., Kimura, N., Inoda, S., Takayama, T., Arai, Y., Yanagi, Y., Shimada, T., Nagai, R., Takahashi, H., & Aizawa, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020556 · Cited by 7
“This effect has been reported with anti-VEGF drugs such as bevacizumab, ranibizumab, and aflibercept [35–39].”
Antal, R., Benyó, Z., Nagy, Z. Z., Kovács, I., Fekete, J. T., Győrffy, B., & Kovács, K. A. (2025) · GeroScience · doi:10.1007/s11357-025-01921-1 · Cited by 6
Self-citation
Metadata
- Authors
- Gyenes, A., István, L., Benyó, F., Papp, A., Resch, M., Sándor, N., Józsi, M., Nagy, Z. Z., Kovács, I., & Kiss, S.
- Affiliations
- Semmelweis University (HU)
- Eötvös Loránd University (HU)
- Cornell University (US)
- Corresponding author
- Kovács, Illés
- Venue
- BMC Ophthalmology
- Published
- 2023-01-10
- Volume
- 23
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1471-2415 (ISSN-L)
- PMC
- PMC9830890
- OpenAlex
- W4313892309
- Cited by
- 9
- References
- 55
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Ophthalmology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Semmelweis University
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- aflibercept, age-related macular degeneration, neutralizing antibodies, aqueous humor, intravitreal injection, anti-VEGF therapy, tachyphylaxis, blood-retinal barrier, choroidal neovascularization, IgG
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Cataract, Humans, Immunoglobulin G, Middle Aged, Recombinant Fusion Proteins, Visual Acuity, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Antibodies, Neutralizing, Wet Macular Degeneration, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration. https://app.cochat.ai/papers/10.1186/s12886-022-02761-9
- The paper
- Gyenes, A., István, L., Benyó, F., Papp, A., Resch, M., Sándor, N., Józsi, M., Nagy, Z. Z., Kovács, I., & Kiss, S. (2023). Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration. BMC Ophthalmology. https://doi.org/10.1186/s12886-022-02761-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

